Fig. 1

SerpinB2 deficiency delays the appearance of the first tumor, reduces the palpable tumor incidence and results in fewer palpable tumors and reduced tumor volume. (A) Representative genotyping of SerpinB2 and PyMT using genomic DNA isolated from the tail samples of wild-type, PyMT, SB2−/− and SB2−/−;PyMT mice. (B) Western blot analysis of ERα and HER2 in MCF 7, SKBR3, and BT474 cells and the tumor lysates of PyMT and SB2−/−;PyMT mice The data are expressed as means ± standard errors from the primary tumors of 3 mice per group. (C) Average time (day) for the appearance of the first palpable tumor in PyMT and SB2−/−;PyMT mice. (D) Percentage of the mice with palpable tumors in PyMT and SB2−/−;PyMT mice by 20 weeks of age after birth. (E) Average number of multifocal palpable tumors in PyMT and SB2−/−;PyMT mice at 8–20 weeks of age. (F) Tumor volumes in the 4th–5th gland of PyMT and SB2−/−;PyMT mice at 8–20 weeks of age. The time-to-first appearance and multifocal numbers of a palpable tumor per mouse are expressed as means ± standard errors from 20 mice per group. *p < 0.05, **0.001 < p < 0.05